Tags : Commercialization

Otsuka Signs a Development and Commercialization Agreement with Esperion for

Shots: Esperion to receive $60M up front, $450M as development & commercial milestone and is eligible to receive 15-30% royalties in the sale of products in Japan. Otsuka will get exclusive rights to Nexletol and Nexlizet and will fund Japan-specific development costs associated with the products The collaboration leverages Esperion’s expertise in lipid management and […]Read More

Zai Lab Signs a Development and Commercialization Agreement with Regeneron

Shots: Regeneron to receive $30M up front and ~$160M as regulatory and commercial milestones. Zai Lab will lead the global development costs of REGN1979 and will receive exclusive rights to develop and commercialize REGN1979 to treat oncology in China, Hong Kong, Taiwan and Macau  The alliance will support the global clinical development of REGN1979, initiating […]Read More

Alvotech Signs an Exclusive Commercialization Agreement with JAMP Pharma for

Shots: JAMP Pharma to get exclusive commercialization rights for Alvotech’s five biosimilars in Canada. Alvotech will take care of full development and commercial supply of the biosimilars from their new state-of-the-art manufacturing facility in Reykjavik, Iceland The focus of the agreement is to strengthen and expand the footprints of JAMP’s generic which is expected to […]Read More

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution

Shots: Mundipharma to get exclusive rights to market and distribute Biosolution’s CartiLife in South Korea. In May 2016, the companies signed commercialization agreement for allogeneic keratinocyte cell therapy product, KeraHeal-Allo and is the second agreement signed presently The focus of the agreement is to include Biosolution’s CartiLife in the Mundipharma’s portfolio of orthopedic care CartiLife […]Read More

Kadmon and Meiji Collaborate to Form JV for the Development

Shots: Kadmon to receive ~$29M as development, regulatory & commercial milestones with royalties on sales of KD025 in Japan and certain other Asian countries The JV, named as Romeck Pharma has the HQ in Japan with shared oversight between Kadmon and Meiji KD025 is ROCK2 inhibitor with the potential to treat inflammatory and fibrotic diseases, […]Read More